MX2022006880A - Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23. - Google Patents

Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.

Info

Publication number
MX2022006880A
MX2022006880A MX2022006880A MX2022006880A MX2022006880A MX 2022006880 A MX2022006880 A MX 2022006880A MX 2022006880 A MX2022006880 A MX 2022006880A MX 2022006880 A MX2022006880 A MX 2022006880A MX 2022006880 A MX2022006880 A MX 2022006880A
Authority
MX
Mexico
Prior art keywords
tnfî
variable domains
single variable
polypeptides
immunoglobulin single
Prior art date
Application number
MX2022006880A
Other languages
English (en)
Inventor
Heidi Rommelaere
Christian Asbrand
Ann Brigé
Sigrid Cornelis
Eric Lorent
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2022006880A publication Critical patent/MX2022006880A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente tecnología tiene como objetivo proporcionar un tipo novedoso de fármaco. Específicamente, la presente tecnología proporciona polipéptidos que comprenden al menos tres dominios variables únicos de inmunoglobulina (ISVD), caracterizados por que al menos un ISVD se une a TNFa y al menos dos ISVD se unen a IL-23. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.
MX2022006880A 2019-12-06 2020-12-03 Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23. MX2022006880A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944619P 2019-12-06 2019-12-06
EP20305056 2020-01-23
EP20000090 2020-02-28
EP20305216 2020-03-02
PCT/EP2020/084430 WO2021110816A1 (en) 2019-12-06 2020-12-03 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23

Publications (1)

Publication Number Publication Date
MX2022006880A true MX2022006880A (es) 2022-07-11

Family

ID=73642903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006880A MX2022006880A (es) 2019-12-06 2020-12-03 Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.

Country Status (13)

Country Link
US (4) US20210188963A1 (es)
EP (1) EP4069733A1 (es)
JP (1) JP2023505492A (es)
KR (1) KR20220122652A (es)
CN (1) CN114981300A (es)
AU (1) AU2020396204A1 (es)
BR (1) BR112022009799A2 (es)
CA (1) CA3163877A1 (es)
CO (1) CO2022009239A2 (es)
IL (1) IL293561A (es)
MX (1) MX2022006880A (es)
TW (1) TW202134269A (es)
WO (1) WO2021110816A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201805288QA (en) 2014-05-16 2018-07-30 Ablynx Nv Improved immunoglobulin variable domains

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334305D1 (de) 1992-08-21 2010-01-28 Univ Bruxelles Immunoglobuline ohne leichte Ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
LT2723771T (lt) 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
IL293155A (en) 2011-06-23 2022-07-01 Ablynx Nv Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
SG10201805288QA (en) 2014-05-16 2018-07-30 Ablynx Nv Improved immunoglobulin variable domains
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CA3002711A1 (en) * 2015-10-22 2017-04-27 Ablynx Nv Gitr agonists
NO2768984T3 (es) 2015-11-12 2018-06-09
AU2016351710B2 (en) 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
CN108699151B (zh) * 2016-02-12 2022-08-12 埃博灵克斯股份有限公司 用于制备免疫球蛋白单可变结构域的方法
US11414480B2 (en) 2016-12-07 2022-08-16 Ablynx N.V. Serum albumin binding immunoglobulin single variable domains
SG11201906264YA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
KR20230165374A (ko) 2017-01-17 2023-12-05 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG

Also Published As

Publication number Publication date
BR112022009799A2 (pt) 2022-08-16
CN114981300A (zh) 2022-08-30
US20220363747A1 (en) 2022-11-17
CA3163877A1 (en) 2021-06-10
US20220372128A1 (en) 2022-11-24
CO2022009239A2 (es) 2022-07-29
JP2023505492A (ja) 2023-02-09
KR20220122652A (ko) 2022-09-02
US20220064281A1 (en) 2022-03-03
TW202134269A (zh) 2021-09-16
US20210188963A1 (en) 2021-06-24
EP4069733A1 (en) 2022-10-12
AU2020396204A1 (en) 2022-07-28
WO2021110816A1 (en) 2021-06-10
IL293561A (en) 2022-08-01
US11332525B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
EP3788068A4 (en) INTERLEUKIN-15 FUSION PROTEINS AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
ZA201903062B (en) Amanitin antibody conjugates
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
WO2018134235A8 (en) Improved serum albumin binders
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EP3782645A4 (en) CANCER T LYMPHOCYTE THERAPY PRODUCT ASSISTING COMPOSITION COMPRISING AN ANTI-CD4 MONOCLONAL ANTIBODY INDUCING CD4+ LYMPHOCYTE DEPLETION AND USE THEREOF
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
WO2019020774A3 (en) NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY
MX2022006881A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
MX2022006880A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
MX2019014400A (es) Inmunoglobulinas que se unen a adamts.